Search

everythinglearnresearchcommunity

for

Search:↓

The user is seeking advice on preserving hair follicles at Norwood stage 6 or 7 while waiting for new treatments. They are considering using treatments like Minoxidil, finasteride, or RU58841.

Regrowth is more likely if hair follicles are still alive, regardless of age, but younger individuals often see better results due to early intervention. Treatments like finasteride, minoxidil, and dermarolling can help, but results vary based on individual factors such as the presence of miniaturized hairs and the speed of treatment initiation.

MCL-1 protein may help maintain hair follicles in the growth phase and prevent miniaturization. There is interest in experimental treatments like exosomes, peptides, or stem cell serums to upregulate MCL-1 for hair loss, especially for those not using minoxidil or finasteride.

Hair loss treatments like Minoxidil, finasteride, and stem cell therapies exist, but a complete cure is hindered by genetic complexity and market dynamics. Cloning hair follicles is considered a potential solution, but it's currently not feasible.

Ultrasound imaging can predict hair shedding and assess hair growth stages by analyzing hair follicle characteristics. The conversation also discusses using ultrasound for personal hair analysis and mentions the potential use of infrared emission for hair treatment.

Hair growth can be induced without stopping DHT, as seen with Minoxidil. HMI115 may work by promoting follicle growth, not targeting the root cause of hair loss (DHT).

Caffeine may promote hair growth and potentially inhibit 5-α-reductase activity in hair follicles, but its effectiveness and systemic impact remain unclear. Users discuss using topical caffeine solutions, with some experiencing no side effects compared to finasteride.

PP405 may promote short-term hair growth by pushing follicles into the growth phase, but concerns exist about long-term effects due to lack of rest phases. Users discuss various treatments like finasteride, minoxidil, spironolactone, alfatradiol, and investigational drugs like KX-826 and GT20029 for hair maintenance and regrowth.

There are no tests to determine genetic follicle sensitivity for hair loss, and conclusions are based on hypothetical or post-balding observations. Finasteride is mentioned as an easy, consistent treatment option compared to natural treatments.

The conversation discusses potential hair loss treatments focusing on stimulating IGF-1 at the follicle level using growth-factor cocktails and engineered peptides, such as Acetyl Tetrapeptide-3, Copper Tripeptide-1, Oligopeptide-20, Thymosin-β4, and Palmitoyl Tetrapeptide-7. It suggests that device-assisted delivery methods like microneedling may enhance effectiveness.

Hair cloning technology is advancing, with clinical trials for improved methods expected by 2028 and 2029, potentially offering a solution for hair loss if donor follicles remain. Organtech's expansion into other biotech areas may secure funding, but the effectiveness of cloning depends on the availability of androgen-resistant donor follicles.

Hair loss may be caused by calcification of capillaries in the scalp, restricting blood flow to hair follicles. A daily treatment regimen including high doses of Vitamins D and K, Magnesium, and Nattokinase could potentially decalcify these capillaries, improving blood flow and hair growth. However, some users warn against excessive Vitamin D intake and emphasize the need for medical consultation.

Hair loss treatments like Minoxidil and Finasteride will still be used even if a cure is found. Hair transplants will continue as cloning new hair follicles will be part of the process.

RepliCel's potential hair loss treatment may cost around $1000 and aims to protect hair follicles from DHT, possibly reversing some miniaturization. It is not considered a cure and may be most effective in early hair loss stages, with its main advantage over finasteride being the lack of sexual side effects.

DHT may inhibit hair growth by affecting mitochondrial function, leading to hair follicle miniaturization. Treatments like minoxidil and PP405 may promote hair growth by altering metabolic pathways, potentially counteracting DHT's effects.

Beard gains from minoxidil are usually permanent due to facial hair follicles' lower sensitivity to DHT. Scalp hair requires ongoing DHT suppression with treatments like finasteride, dutasteride, and RU58841 to maintain gains after stopping minoxidil.

PP405 is not a cure for hair loss but may reactivate dormant hair follicles, similar to minoxidil. It is unlikely to help with miniaturized or vellus hairs and is still in trial phases, with availability expected around 2030.

Fluridil may decrease the number of androgen receptors in hair follicles by up to 95%. This suggests a different action mechanism from other non-steroidal antiandrogens like RU58841, indicating they might be used together.

TWIST-1 gene's role in hair loss and potential as a treatment target. Inhibiting TWIST-1 may prolong hair growth and reduce hair follicle sensitivity to DHT.

The conversation discusses hair loss where only short, thin hairs are being shed after 16 weeks of using dutasteride, with no visible regrowth. One response suggests that shedding short hairs is a positive sign, indicating that the hair follicles are still active and responding to treatment.

High DHEA levels may contribute to hair loss by increasing DHT in hair follicles, potentially explaining why finasteride is ineffective for some. Treatments like high-dose dutasteride and RU58841 are suggested, but the underlying cause, such as adrenal issues, should be investigated.

KY19382 is discussed as a potential treatment for creating new hair follicles and possibly curing hair loss. The conversation seeks user experiences and sourcing information for KY19382.

PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.

Pelage PP405 is a new hair loss treatment in trials, potentially reactivating dormant hair follicles without affecting hormones. Results are expected in February 2025, offering an alternative to minoxidil and finasteride.

Finasteride prevents further hair loss by blocking DHT, while minoxidil stimulates hair growth by prolonging the active phase of hair follicles. Stopping minoxidil can lead to loss of regrown hair because finasteride does not address the same growth mechanism.

Finasteride stops hair loss by blocking DHT, while Minoxidil promotes hair growth by increasing blood flow to hair follicles. Using both can help regrow hair, but results vary by individual.

TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.

The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.

Nanoxidil may be more effective than Minoxidil for hair loss due to better follicle penetration, but it lacks widespread recognition and research because it's owned by a small company and classified as a cosmetic. The pharmaceutical system favors Minoxidil due to its established market presence and profitability, leaving Nanoxidil largely unstudied and unknown.

PP405 is being discussed as a potential new approach to hair loss by targeting follicle stem cells, suggesting a different mechanism from existing treatments like finasteride and minoxidil. However, there is skepticism about whether it will lead to meaningful long-term outcomes or follow the pattern of previous treatments that showed promise but lacked consistent results.